Pliant Therapeutics appoints David Raben as chief medical officer
PLRX•Pliant Therapeutics named David Raben chief medical officer, effective Sept. 30, 2026. He most recently served as chief medical officer at Bicara Therapeutics.
1. Raben’s experience
Raben most recently led clinical development of ficerafusp alfa (BCA101) as chief medical officer at Bicara Therapeutics. He previously held senior oncology development roles at Amgen, led late-stage oncology programs at Genentech and was a professor at the University of Colorado Cancer Center.
